An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults

Influenza and other Respiratory Viruses

Volumn 7, Issue 1, 2013, Pages 66-73

  Talaat, Kawsar R ^a   Karron, Ruth A ^a   Liang, Philana H ^a   Mcmahon, Bridget A ^a   Luke, Catherine J ^b   Thumar, Bhagvanji ^a   Chen, Grace L ^b   Min, Ji Young ^b   Lamirande, Elaine W ^b   Jin, Hong ^c   Coelingh, Kathy L ^c   Kemble, George W ^c   Subbarao, Kanta ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MEDIMMUNE   (United States)

Author keywords

H2N2; Human; Influenza; Influenza vaccine; Live attenuated influenza vaccines; Neuraminidase inhibition

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS A H2N2 VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACKACHE; BLOATING; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GASTROENTERITIS; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFECTION; INFLUENZA A (H2N2); INFLUENZA VIRUS A H2N2; LOOSE FECES; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NOSE OBSTRUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHOULDER PAIN; SORE THROAT; TACHYCARDIA; TREATMENT RESPONSE; VIRUS CULTURE; VIRUS REPLICATION; VOMITING;

ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; VIRUS REPLICATION; VIRUS SHEDDING; YOUNG ADULT;

EID: 84871397055     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2012.00350.x     Document Type: Article

References (35)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733-1745.
2. CDC. CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April-January 16, 2010. Atlanta: CDC, 2010. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm (cited 23 February 2010).
3. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 1978; 87:13-20.
4. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989; 63:4603-4608.
5. Rajagopal S, Treanor J. Pandemic (avian) influenza. Semin Respir Crit Care Med 2007; 28:159-170.
6. Dunn FL. Pandemic Influenza in 1957: review of International Spread of New Asian Strain. JAMA 1958; 166:1140-1148.
7. Golubev DB, Karpukhin GI, Galitarov SS, Denisov GM. Type A influenza (H2N2) viruses isolated in Leningrad in 1980. J Hyg (Lond) 1985; 95:493-504.
8. Nelson R. Influenza A H2N2 saga remains unexplained. Lancet Infect Dis 2005; 5:332.
9. Schrauder A, Schweiger B, Buchholz U et al. Laboratory exposure to influenza A H2N2, Germany, 2004-2005. Emerg Infect Dis 2006; 12:1997-1998.
10. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 1967; 213:612-614.
11. Kitayama T, Togo Y, Hornick RB, Friedwald WT. Low-temperature-adapted influenza A2/AA/6/60 virus vaccine in man. Infect Immun 1973; 7:119-122.
12. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137-144.
13. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-696.
14. US FDA. February 3, 2010 Approval Letter - Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC). 2010. Available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201995.htm (cited 20 December 2011).
15. Karron RA, Callahan K, Luke C et al. A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults. J Infect Dis 2009; 199:711-716.
16. Talaat KR, Karron RA, Callahan KA et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 2009; 27:3744-3753.
17. Karron RA, Talaat K, Luke C et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953-4960.
18. WHO. Tables on the Clinical trials of pandemic influenza prototype vaccines, 2009. Available at http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/index.html (accessed 25 August 2009, 23 February 2010).
19. Murphy BR, Tierney EL, Barbour BA et al. Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines. Infect Immun 1980; 29:342-347.
20. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-943.
21. Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983; 40:1044.
22. Sasaki S, Jaimes MC, Holmes TH et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-228.
23. Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses 2009; 3:233-240.
24. Lai KK, Cook L, Wendt S, Corey L, Jerome KR. Evaluation of real-time PCR versus PCR with liquid-phase hybridization for detection of enterovirus RNA in cerebrospinal fluid. J Clin Microbiol 2003; 41:3133-3141.
25. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007; 7:267-278.
26. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-409.
27. Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26:4299-4303.
28. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-1137.
29. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004; 3:643-654.
30. Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011; 72:463-469.
31. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, van Beest Holle Mdu R, Koopmans M. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods 2006; 132:113-120.
32. Chen GL, Lamirande EW, Jin H, Kemble G, Subbarao K. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. Virology 2010; 398:109-114.
33. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002; 20:1340-1353.
34. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5:67-75.
35. Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009; 27:1101-1110.